ROLE OF GABAPENTINOIDS AMONG PATIENTS WITH CHRONIC PRURITUS
Phase 4
- Conditions
- Health Condition 1: L299- Pruritus, unspecified
- Registration Number
- CTRI/2022/10/046189
- Lead Sponsor
- ot applicable
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Persistent pruritus for 6 weeks & above
Exclusion Criteria
1. Patients with AST and ALT three times above the normal level
2. Creatinine clearance (Crcl) <30 ml/min
3. Patients with pruritus of known dermatological causes such as Psoriasis, Lichen planus, Scabies, etc
4. Pregnant and lactating women
5. Patients taking opioids for therapeutic purpose
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method VISUAL ANALOGUE SCALETimepoint: BASELINE, 2ND WEEK AND 6TH WEEK
- Secondary Outcome Measures
Name Time Method 5D Pruritus Scale and Dermatology Life Quality IndexTimepoint: BASELINE, 2ND WEEK AND 6TH WEEK